WICHITA, Kan., July 24, 2019 /PRNewswire/ -- Rhea Rogers, MD with Medical Innovative Solutions for Beauty, Intimacy &Wellness (MISBIW) is implementing a non-invasive and drug-free solution for Erectile Dysfunction (ED). This cutting-edge procedure boasts a 75% success rate amongst patients. The treatment is called

LOVELAND, Colo., July 24, 2019 /PRNewswire/ -- James Howton, DO with Restore Health Center is implementing a non-invasive and drug-free solution for Erectile Dysfunction (ED). This cutting-edge procedure boasts a 75% success rate amongst patients. The treatment is called

SHANGHAI, July 24, 2019 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, today announced the signing of a strategic cooperation agreement with Harbin Pharmaceutical Group Holding Co., Ltd. (HPGC, SHSE: 600664), which has selected 111 as its primary partner for online sales of Over the Counter (O

FRISCO, Texas, July 24, 2019 /PRNewswire/ -- Addus HomeCare Corporation (Nasdaq: ADUS), a provider of comprehensive home care services, announced today that James "Zeke" Zoccoli will retire from his position as Chief Information Officer, effective July 31, 2019.  Mike Wattenbarger, Vice President

IRVINE, Calif., July 24, 2019 /PRNewswire/ -- Pathnostics, a diagnostic solutions company, announced today that its board of directors has appointed Samuel D. Riccitelli

SAN FRANCISCO, July 24, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of its Detect programs to provide no-charge genetic testing for conditions i

SUNNYVALE, Calif., July 24, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies validating the benefits of CyberKnife® and

TORONTO, July 24, 2019 /PRNewswire/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF)

MISSISSAUGA, ON, July 24, 2019 /PRNewswire/ - ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced access to high quality, niche-established medicines, today announced it intends to release its second quarter, 20

PALO ALTO, Calif., July 24, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that data from the ongoing KSI-301 clinical study will be presented at the American Society of Retina Specialists (ASRS) 2019 Annual Meet